Chitosan functionalized selenium nanoconjugates of Mucuna pruriens as a nanotherapeutic approach for Parkinson’s disease
4 affiliations
- 1School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha India
- 2Amity Institute of Pharmacy, Amity University, Kolkata, West Bengal India
- 3L. M. College of Pharmacy, Ahmedabad, Gujarat India
- 4GITAM School of Pharmacy, GITAM Deemed to be University, Visakhapatnam, Telangana India
Abstract
Nature’s mother holds many untapped treasures of phytoconstituents that can cure and exhibit unexpected therapeutic activity against several diseases. Seeds of velvet beans, popularly known as Mucuna pruriens (MP), are the richest source of Levodopa (L-DOPA). L-DOPA is the precursor for dopamine, a key neurotransmitter deficient in the brain of patients suffering from Parkinson’s disease (PD). The peripheral degradation of L-DOPA before crossing the blood-brain barrier (BBB) is the greatest challenge in the treatment of PD patients. Several preclinical and clinical studies reported the excellent efficacy of MP seed extracts. To deliver the key constituents of MP seed extracts, the research work designed a nanocomposite containing a trace element (selenium), a natural polysaccharide polymer (chitosan), and MP seed extract. The efficacy of the Chitosan@selenium Mucuna pruriens NPs (CSMNPs) was evaluated at two dose levels (25 and 50 mg•kg− 1) in the reserpine-induced PD rat model, compared with MP extract and selenium NPs of Mucuna pruriens (MSNPs). The surface-modified polymeric metal NPs showcased improved motor function, grip strength, and antioxidant levels in the reserpine-induced PD rat model, significantly. In comparison to MP extract and MSNPs, the CSMNPs showed better antiparkinsonian and antioxidant properties, which may be attributed to their smaller size and better permeability through the BBB. Histopathological assessment of the hippocampus and the substantia nigra of the brain also supported the results of CSMNPs.
Related
- Sulfonic acid-functionalized chitosan-Fe3O4/covalent triazine framework as an efficient and reusable magnetic nano-catalyst for fructose conversion into 5-hydroxymethylfurfural
- Folic Acid-Functionalized Chitosan-Coated Oleosomes Engineered for Enhanced Anti-Arthritic Delivery of Syzygium cumini Seed Extract.
- Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.
- NIR-responsive cetuximab-functionalized chitosan-polydopamine hydrogel Co- delivering Ca²⁺ and gefitinib for EGFR-targeted esophageal cancer therapy via Ca²⁺- mediated cytotoxicity and potential immunomodulatory effects.
- Nanotherapeutic macrophage reprogramming through immunometabolic and microbial modulation for sepsis treatment.
BibTeX
@article{sahoo2026chitosan,
title = {{Chitosan functionalized selenium nanoconjugates of Mucuna pruriens as a nanotherapeutic approach for Parkinson’s disease}},
author = {Saswati Swagatika Sahoo and Srijita Modak and Pratap Kumar Sahu and Anindita Behera and Ketan M. Ranch and Ranjit Prasad Swain},
journal = {Discover Nano},
year = {2026},
month = nov,
doi = {10.1186/s11671-026-05114-3},
url = {https://doi.org/10.1186/s11671-026-05114-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Chitosan functionalized selenium nanoconjugates of Mucuna pruriens as a nanotherapeutic approach for Parkinson’s disease
AU - Saswati Swagatika Sahoo
AU - Srijita Modak
AU - Pratap Kumar Sahu
AU - Anindita Behera
AU - Ketan M. Ranch
AU - Ranjit Prasad Swain
PY - 2026
DA - 2026/11/04
JO - Discover Nano
DO - 10.1186/s11671-026-05114-3
UR - https://doi.org/10.1186/s11671-026-05114-3
AB - Nature’s mother holds many untapped treasures of phytoconstituents that can cure and exhibit unexpected therapeutic activity against several diseases. Seeds of velvet beans, popularly known as Mucuna pruriens (MP), are the richest source of Levodopa (L-DOPA). L-DOPA is the precursor for dopamine, a key neurotransmitter deficient in the brain of patients suffering from Parkinson’s disease (PD). The peripheral degradation of L-DOPA before crossing the blood-brain barrier (BBB) is the greatest challenge in the treatment of PD patients. Several preclinical and clinical studies reported the excellent efficacy of MP seed extracts. To deliver the key constituents of MP seed extracts, the research work designed a nanocomposite containing a trace element (selenium), a natural polysaccharide polymer (chitosan), and MP seed extract. The efficacy of the Chitosan@selenium Mucuna pruriens NPs (CSMNPs) was evaluated at two dose levels (25 and 50 mg•kg− 1) in the reserpine-induced PD rat model, compared with MP extract and selenium NPs of Mucuna pruriens (MSNPs). The surface-modified polymeric metal NPs showcased improved motor function, grip strength, and antioxidant levels in the reserpine-induced PD rat model, significantly. In comparison to MP extract and MSNPs, the CSMNPs showed better antiparkinsonian and antioxidant properties, which may be attributed to their smaller size and better permeability through the BBB. Histopathological assessment of the hippocampus and the substantia nigra of the brain also supported the results of CSMNPs.
SN - 2731-9229
ER -